~tc~ disabled March 7, 2018 ~/tc~ ~tc~ ~/tc~ ~tc~ Disabled March 7 2018 ~/tc~
Register Log In Login with facebook

Following breast cancer 100,000 IU Vitamin D doses helped a lot (standard of care 400 IU daily did not) – RCT July 2016

Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study.

Ann Oncol. 2016 Jul;27(7):1235-41. doi: 10.1093/annonc/mdw145. Epub 2016 Mar 30.
Jacot W1, Firmin N2, Roca L3, Topart D4, Gallet S2, Durigova A2, Mirr S2, Abach L3, Pouderoux S2, D'Hondt V2, Bleuse JP3, Lamy PJ5, Romieu G2.

  • The RCT found that 100,000 IU every two weeks is good
  • 150,000 IU every two weeks or 100,000 IU weekly would get most Cancer patients >30 ng   and many > 40 ng - which should be the minimum target

Note: 6 month is also far too long be help during surgery or subsequent BC treatment

Note: Vitamin D becomes even lower after surgery and subsequent treatment of Breast Cancer

See also VitaminDWiki

Breast Cancer Prevention

 Download the PDF from VitaminDWiki

100,000 IU = doubleheaded arrow


400 IU daily ==> 16% above 30ng

   27% were still <20 ng


100,000 IU every two weeks (avg 7,000 IU daily) ==> 38% above 30 ng

   only 4% were still <20 ng


A minority of early breast cancer (EBC) patients treated with adjuvant or neoadjuvant chemotherapy have sufficient baseline vitamin D (vitD) level. This randomized phase III study assessed the safety and efficacy of a tailored, high-dose, oral vitD supplementation in restoring a normal 25-hydroxy vitD (25OHD) level in this population.

Participants received a 6-month conventional (C) vitD and calcium supplementation or a 6-month high-dose oral vitD regimen tailored on the deficiency (T) and a conventional calcium supplementation. The primary end point was the 6-month percentage of 25OHD serum level normalization.

A total of 215 patients including 197 patients with vitD deficiency were recruited, and 195 patients were randomized (T, 100; C, 95). Compliance to the daily oral supplementation was 68.4% and 67% in the C and T arms, respectively. Discontinuous high-dose vitD compliance appeared higher in the T arm (77%). At 6 months, more patients presented with a normalized vitD level in the T arm (30% versus 12.6%; P = 0.003). Supplementation was well tolerated, and no significant difference in the treatment-related toxicity between the two arms was reported. Fifty-two patients without vitD normalization from the C arm switched to the T arm after 6 months. At 12 months, 44% of these patients achieved vitD normalization.

A tailored high-dose oral vitD supplementation safely allows a higher percentage of the serum 25OHD level normalization compared with a conventional regimen in chemotherapy-treated EBC patients. As compliance to a daily oral supplementation remains poor in this setting, an adaptation of the treatment schedule is warranted.

CLINICAL TRIAL NUMBER: NCT01480869.   PMID: 27029707 DOI: 10.1093/annonc/mdw145

Created by admin. Last Modification: Sunday December 31, 2017 21:02:58 UTC by admin. (Version 17)

Attached files

ID Name Comment Uploaded Size Downloads
9085 Tailored 100,000.jpg admin 31 Dec, 2017 20:45 45.33 Kb 47
9084 Tailored.jpg admin 31 Dec, 2017 18:56 24.36 Kb 50
9083 Conventional.jpg admin 31 Dec, 2017 18:56 25.72 Kb 47
9081 Tailored BC.pdf admin 31 Dec, 2017 18:55 277.05 Kb 19
See any problem with this page? Report it to the webmaster.